ArticleBioinformatics and biology insights2026
Integrating AI-Based Clustering, Molecular Dynamics, and Binding Energy Analysis to Elucidate Conformational Dynamics and Binding Selectivity in Extracellular Signal-Regulated Kinases 1 and 2 Complexes.
Article in Bioinformatics and biology insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational Modeling and MM-PBSA-Based Molecular Dynamics Investigation of Unexplored tRNA Isoleucine Lysidine Synthetase from Mycobacterium tuberculosis with Hyperbranched Amoxicilloyl-Poly-L-Lysine.Journal of molecular modeling · 2026Article
- Identification of Natural Flavonoids Targeting PLK-1 as Potential Anti-Metastatic Agents: A Computational Approach.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of selective small-molecule inhibitors against extracellular signal-regulated kinases 1 and 2 (ERK1/2) remains a major challenge due to their high structural similarity and conformational flexibility. In this study, we combined classical molecular dynamics (MD) simulations with artificial intelligence (AI)-based unsupervised learning approaches to investigate the conformational dynamics and binding selectivity of ERK1/2-inhibitor complexes. Six systems, comprising ERK1 and ERK2 bound to inhibitors 33A, 38Z, and Z48, were simulated for 250 ns to capture their structural and energetic behaviors. Root mean square deviation (RMSD) and fluctuation (RMSF) analyses confirmed that all complexes reached equilibrium, with ERK2 systems exhibiting greater structural stability than ERK1. Radius of gyration (Rg) and hydrogen-bond profiles support consistent compactness and persistent interactions throughout the trajectories. The AI-based dimensionality reduction (principal component analysis [PCA], t-distributed stochastic neighbor embedding [t-SNE]) and K-means clustering revealed distinct conformational basins, indicating ligand-specific modulation of ERK flexibility. Free energy landscape mapping and state transition analyses demonstrated that Z48-bound systems showed more compact and stable conformational basins, reflecting enhanced conformational stabilization, whereas 33A complexes exhibited higher dynamic variability. In contrast, molecular mechanics/generalized Born surface area (MM/GBSA) binding free energy calculations showed that 38Z exhibits the strongest binding affinity toward both ERK isoforms, driven primarily by favorable van der Waals interactions. Overall, this combined MD-AI framework provides atomistic insights into ERK1/2 conformational plasticity and inhibitor selectivity, highlighting 38Z as the most energetically favorable binder and Z48 as the most effective conformational stabilizer. These findings advance the understanding of ERK regulation and can guide the rational design of next-generation selective kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.